Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/12160
Title: What is the optimum thiamine dose to treat or prevent Wernicke's Encephalopathy or Wernicke-Korsakoff Syndrome?: Results of a randomised controlled trial.
Authors: Dingwall, Kylie M
Delima, Jennifer F
Binks, Paula
Batey, Robert
Bowden, Stephen C
Citation: This article is protected by copyright. All rights reserved.
Alcohol Clin Exp Res. 2022 Apr 15. doi: 10.1111/acer.14843.
Abstract: BACKGROUND: The primary cause of Wernicke Korsakoff Syndrome (WKS) is thiamine deficiency, and more than 90% of cases are reported in alcohol dependent patients. Whilst observational studies show parenteral thiamine administration results in drastic reduction in mortality, relevant treatment trials have never been conducted to determine the optimum thiamine dose. METHODS: Two double blind, parallel groups, randomised controlled trials (RCTs) were conducted to determine the optimal thiamine dose required for 1) the prevention of Wernicke's Encephalopathy (WE), the acute phase of WKS, in asymptomatic but 'at-risk' alcohol misuse patients (Study 1) and 2) the treatment of WE in symptomatic alcohol misuse patients (Study 2). Each study had a dosage regimen comprising three parenteral thiamine doses which were allocated at a ratio of 1:1:1. Study 1 Asymptomatic At-risk patients (N = 393) received either 100mg daily, 100mg thrice daily, or 300 mg thrice daily, for 3 days. Study 2 Symptomatic patients (N=127) received either 100mg thrice daily, 300mg thrice daily or 500 mg thrice daily, for five days. Cognitive function was the primary outcome, assessed using the Rowland Universal Dementia Assessment Scale (RUDAS), two Cogstate subtests, and an adapted Story Memory Recall test. Secondary analyses examined differences in neurological function (ataxia, oculomotor abnormalities and confusion) at follow up. RESULTS: No significant differences were observed between any of the dosage conditions for either Study 1 or Study 2 on cognition or neurological functioning. This real-world study found that having a clinically unwell target population with high comorbidity and multiple presentations, coupled with challenges in cross cultural assessment is likely to complicate RCT findings. CONCLUSIONS: The results of this study showed no clear benefit of high dose thiamine over intermediate or lower doses of thiamine, over the time intervals examined, for the treatment and prevention of cognitive and neurological abnormalities related to WKS. Several study limitations temper the interpretation of these findings. Nevertheless, the absence of conclusive evidence for the superiority of high dose thiamine supports a recommendation for patient-specific treatment, whilst ensuring that the potential impact of other biochemical factors (e.g. magnesium, other B vitamin deficiencies) are considered and corrected if necessary.
Click to open Pubmed Article: https://pubmed-ncbi-nlm-nih-gov.www.ezpdhcs.nt.gov.au/35428992/
Journal title: Alcoholism, clinical and experimental research
Publication Date: 2022-04-15
Type: Journal Article
URI: https://hdl.handle.net/10137/12160
DOI: 10.1111/acer.14843
Orcid: 0000-0002-7841-4751
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing